3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Classical hematology
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Hematologic Neoplasms
2
Myocarditis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Febrile Neutropenia
1
Disease
1
Interventions
Cytarabine
2
venetoclax
1
pembrolizumab
1
obinutuzumab
1
neratinib
1
idelalisib
1
ibrutinib
1
gilteritinib
1
Surveys and Questionnaires
1
Positron Emission Tomography Computed Tomography
1
Mitoxantrone
1
Interleukin-15
1
Gemtuzumab
1
Daunorubicin
1
CPX-351
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Positron Emission Tomography Computed Tomography
×
Other hematologic neoplasm
×
Clear all
NCT03429387
2022-05-17
PIPPIN
Peter MacCallum Cancer Centre, Australia
Phase NA
Completed
147 enrolled